Topics

Truxima, a rituximab biosimilar, to be available in the US next week

04:44 EST 8 Nov 2019 | SmartBrief

Truxima, the first rituximab biosimilar approved by the FDA to treat chronic lymphocytic leukemia and B-cell non-Hodgkin lymp -More

Original Article: Truxima, a rituximab biosimilar, to be available in the US next week

NEXT ARTICLE

More From BioPortfolio on "Truxima, a rituximab biosimilar, to be available in the US next week"

Quick Search

Relevant Topics

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...